Pier Luigi Zinzani

机构：IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, Istituto di Ematologia di Bologna, Azienda USL di Bologna, Istituto Oncologico Romagnolo, University of Bologna · ORCID：0000-0002-2112-2651

发表论文 1852 篇 · 总被引 63214 次 · h-index 119

代表论文

• Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma (2026 · Journal of Clinical Oncology · 被引 1)
• Development and Validation of the Idiopathic Multicentric Castleman Disease Symptom Burden Scale (ISBUS): Protocol for an International Multistage Mixed Methods Study (2026 · JMIR Research Protocols)
• Correction to: Modern and multidisciplinary care in polycythemia vera (2026 · Annals of Hematology)
• Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial (2026 · Blood Advances)
• Glofitamab in Heavily Pretreated Mantle Cell Lymphoma Patients: A Multicenter Real‐World Case Series (2026 · eJHaem)
• Fixed-duration pirtobrutinib plus venetoclax–rituximab versus venetoclax–rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial (2026 · The Lancet)